M.01
Small molecules
Virtual screening, generative chemistry, predicted ADMET, synthesis prioritization. Closed-loop hit-to-lead optimization with a hand-off package ready for experimental validation.
The Brioche platform is built around an intent abstraction. Whatever the question — small molecule against an oncology kinase, ASO for a rare metabolic disease, peptide for an autoimmune target, biologic for a cardiovascular indication — the same engine handles it. The intent object changes; the stack does not.
The Discovery Engine ingests a target and a context object and returns optimized therapeutic matter against that target. Modality is a parameter of the intent, not a constraint of the engine.
Virtual screening, generative chemistry, predicted ADMET, synthesis prioritization. Closed-loop hit-to-lead optimization with a hand-off package ready for experimental validation.
Sequence design against the target, predicted developability profile, immunogenicity assessment, formulation context. Hand-off ready for upstream and downstream development.
ASOs, siRNAs, mRNA constructs. Sequence design against the genomic target, predicted off-target profile, delivery and chemistry context. Precedent-aware (milasen-class IND pathway and beyond).
Epitope analysis, candidate antibody design against structurally characterized targets, predicted developability, sequence liability profiling.
Construct strategy, target rationale, regulatory and manufacturing precedent — for autologous and allogeneic programs.
Combination regimens, antibody-drug conjugates, bispecifics, modality combinations. Same intent abstraction, multiple molecular components.
Therapeutic area is also a parameter, not a constraint. The same engine reads the published failure record, the regulatory precedent, and the competitive set across every area below — and onboards new areas with the same source coverage and review process.
Solid tumors and hematologic malignancies. First validated proof point — solid tumor target with clinical-grade endpoints. Deep coverage of the FDA precedent set.
Genetic and metabolic rare diseases with bounded patient populations and well-characterized molecular drivers. Patient-specific therapeutic context built in.
Autoimmune indications across rheumatology, dermatology, gastroenterology. Comparator landscape includes biologics, JAK inhibitors, and emerging modalities.
Metabolic and endocrine disease — diabetes, obesity, hepatic disease, thyroid. Long regulatory precedent record and active comparator set.
Neurodegenerative, psychiatric, pain, and rare neurological indications. Heavy focus on biomarker validation and trial design precedent.
Cardiovascular and renal indications — heart failure, hypertension, chronic kidney disease, comorbid conditions. Extensive regulatory precedent record.
Antimicrobial and antiviral discovery. Resistance landscape, regulatory pathway differences (LPAD, GAIN), and competitive set.
Reproductive, maternal-fetal, and women's health indications — historically under-served, now a growing precedent record.
Pediatrics, dermatology, ophthalmology, hearing & vision, GI — scoped per engagement at kickoff. The platform absorbs new areas as the practice extends.